Arginase 1 is a marker of protection against illness in contacts of leprosy patients.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
12 05 2022
12 05 2022
Historique:
received:
02
02
2022
accepted:
28
04
2022
entrez:
13
5
2022
pubmed:
14
5
2022
medline:
18
5
2022
Statut:
epublish
Résumé
Leprosy household contacts are generally more prone to develop the disease compared to the general population. Previous studies have demonstrated that genes related to the alternative activation (M2) profile in macrophages are associated with the increased bacillary load in multibacillary leprosy patients (MB), and that contacts of MB patients have a higher risk of contracting the disease. In addition, positive serological responses to PGL-1 or LID-1 are associated with a higher risk of disease. We performed a 5-year follow-up of contacts of leprosy patients and evaluated the pattern of gene and protein expression in cells from contacts that developed leprosy during this period. Leprosy household contacts had decreased soluble CD163 and heme oxygenase 1 (HO-1) serum levels when compared with healthy donors and leprosy patients. In contrast, arginase 1 activities were higher in contacts when compared with both healthy donors and leprosy patients. Of the contacts, 33 developed leprosy during the follow-up. Gene expression analysis revealed reduced ARG1 expression in these contacts when compared with contacts that did not develop disease. Arginase activity was a good predictive marker of protection in contacts (sensitivity: 90.0%, specificity: 96.77%) and the association with serology for anti-PGL-1 and anti-LID-1 increased the sensitivity to 100%. Altogether, the data presented here demonstrate a positive role of arginase against leprosy and suggest that the evaluation of arginase activity should be incorporated into leprosy control programs in order to aid in the decision of which contacts should receive chemoprophylaxis.
Identifiants
pubmed: 35552484
doi: 10.1038/s41598-022-11944-9
pii: 10.1038/s41598-022-11944-9
pmc: PMC9098644
doi:
Substances chimiques
Antibodies, Bacterial
0
Antigens, Bacterial
0
Biomarkers
0
Glycolipids
0
Arginase
EC 3.5.3.1
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
7850Informations de copyright
© 2022. The Author(s).
Références
EBioMedicine. 2021 Jun;68:103379
pubmed: 34090257
PLoS One. 2010 Nov 19;5(11):e14061
pubmed: 21124916
Infect Immun. 2014 Sep;82(9):3968-78
pubmed: 25024361
Mem Inst Oswaldo Cruz. 2012 Dec;107(8):1054-9
pubmed: 23295758
Am J Trop Med Hyg. 2008 Mar;78(3):518-21
pubmed: 18337353
PLoS Negl Trop Dis. 2016 Sep 22;10(9):e0004934
pubmed: 27658042
PLoS Negl Trop Dis. 2017 May 3;11(5):e0005560
pubmed: 28467415
Clin Vaccine Immunol. 2007 Nov;14(11):1400-8
pubmed: 17898185
Rev Bras Epidemiol. 2021 Jun 30;24:e210039
pubmed: 34231829
PLoS Negl Trop Dis. 2012;6(6):e1711
pubmed: 22724040
BMC Infect Dis. 2015 May 30;15:219
pubmed: 26024906
BMJ Open. 2021 Aug 26;11(8):e046125
pubmed: 34446483
Immunol Rev. 2021 May;301(1):175-192
pubmed: 33709405
Microbes Infect. 2017 Nov;19(11):505-514
pubmed: 28684130
Trans R Soc Trop Med Hyg. 2008 Jul;102(7):631-8
pubmed: 18514242
Eur J Immunol. 2012 Nov;42(11):2925-36
pubmed: 22851198
PLoS Negl Trop Dis. 2016 May 18;10(5):e0004703
pubmed: 27192199
Mem Inst Oswaldo Cruz. 2004 Aug;99(5):509-11
pubmed: 15543415
Indian J Dermatol Venereol Leprol. 2020 Mar-Apr;86(2):115-123
pubmed: 31975697
J Immunol. 1991 Sep 1;147(5):1642-6
pubmed: 1880420
Sci Rep. 2019 Dec 30;9(1):20304
pubmed: 31889120
Front Immunol. 2020 Aug 11;11:1811
pubmed: 32849645